Jim Simons’s Aardvark Therapeutics AARD Stock Holding History

Jim Simons’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-70,792	Closed	-$267K	–	3729
2026 Q1	$267K	Buy	+70,792	New	+$734K	﹤0.01%	2834

Other funds holding AARD

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Jim Simons's AARD Position: Q2 2026 in Review

Jim Simons sold out of Aardvark Therapeutics (AARD) in Q2 2026, closing a stake of 70,792 shares — an estimated $267K sold.

Jim Simons first reported a position in AARD in Q1 2026 and held it in 1 quarter. The position peaked at $267K in Q1 2026. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

Jim Simons reported no remaining Aardvark Therapeutics position as of Q2 2026 after selling out during the quarter.
Jim Simons sold 70,792 Aardvark Therapeutics shares in Q2 2026, an estimated $267K.
Jim Simons first reported a position in Aardvark Therapeutics in Q1 2026 and held it in 1 quarter.
Jim Simons's Aardvark Therapeutics position peaked at $267K in Q1 2026.
71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.